Safety and tolerability of topical trametinib in rosacea: Results from a phase I clinical trial
Abstract Purpose Overactivation of the mitogen activated kinase pathway has been associated with rosacea. We hypothesised that inhibitors of this pathway can be repurposed to alleviate rosacea symptoms. Methods In order to test this hypothesis, we designed a double‐blind, randomised, placebo‐control...
Saved in:
Main Authors: | Edward J. Wladis (Author), Jacqueline Busingye (Author), Leahruth K. Saavedra (Author), Amy Murdico (Author), Alejandro P. Adam (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SH2 domain‐containing protein tyrosine phosphatase‐2 is enriched in eyelid specimens of rosacea
by: Apoorv Chebolu, et al.
Published: (2023) -
Treatment-refractory cutaneous Rosai-Dorfman disease responsive to oral methotrexate and topical trametinib
by: Christopher J. Fay, BA, et al.
Published: (2023) -
Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials
by: Muñoz-Villegas P, et al.
Published: (2021) -
Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma
by: Mélanie Saint-Jean, et al.
Published: (2018) -
The combination of dabrafenib/trametinib is approved for the treatment of pediatric glioma
by: article Editorial
Published: (2023)